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We have earlier shown that the estrogen-modulated ribo-
flavin carrier protein (RCP) first isolated from the chicken
egg is evolutionarily conserved in mammals and is elaborated
by lactating mammary gland as demonstrated with rat mam-
mary epithelial cells in culture and confirmed by isolation of
the vitamin carrier from bovine milk. In view of several
earlier reports that many milk proteins as well as other
estrogen-inducible proteins are up-regulated and secreted
into circulation in animal models and in women with neoplas-
tic breast disease, we analyzed serum RCP levels in a double-
blind study using a specific radioimmunoassay in pre- and
post-menopausal women with clinically diagnosed breast
cancer at early and advanced stages of the disease and com-
pared these levels with those in normal age-matched control
volunteers. Our data reveal that the serum RCP levels in
cycling breast cancer patients are 3- to 4-fold higher (p <
0.01) than those in their normal counterparts. This difference
in circulatory RCP levels between cancer patients and their
age-matched normal counterparts is further magnified to 9-
to 11-fold (p < 0.005) at the post-menopausal stage. In addi-
tion, there seems to be a good correlation between rising
RCP levels and disease progression, since significantly higher
RCP concentrations (p < 0.005) are encountered in patients
with advanced metastasizing breast cancer versus those with
early disease. Using specific monoclonal antibodies, RCP
could be localized immunohistochemically in the cytoplasm
of invading neoplastic cells of lobular and ductal carcinomas
of the breast, indicating that the malignant cells are probably
the source of the elevated serum RCP levels in breast cancer.
These findings suggest that measurement of circulatory RCP
and the immunohistochemical staining pattern of RCP in
biopsy specimens could be exploited as an additional marker
in diagnosis/prognosis of breast cancer in women.
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Riboflavin carrier (or binding) protein (RCP) is an estrogen-
inducible phospho-glycoprotein (Mr 37 K) required in egg-laying
vertebrates for yolk deposition of the vitamin to support growth
and development of the prospective embryo.1 The vitamin carrier
is evolutionarily conserved in mammals including sub-human pri-
mates and humans2 and plays a pivotal role in embryonic devel-
opment during gestation. Interference with its function by active or
passive immunization results in early embryonic loss and preg-
nancy curtailment.3,4 Riboflavin concentration in mammalian milk
is several fold higher than in the maternal circulation during
lactation,5 even though the circumferential tight junctions between
mammary epithelial cells constitute a barrier for free passage of
blood constituents.6 It was therefore attractive to hypothesize that
RCP is elaborated by the lactating mammary gland, an estrogen
target tissue, to sequester the vitamin and for secretion into milk
for neonatal nutrition. This working hypothesis was amply sup-
ported by research in our laboratory,1,7 which showed that: (i) RCP
can be detected and assayed in the milk of rodents, cows, bonnet
monkeys and humans by using a sensitive and specific radioim-
muno assay; (ii) it can be bulk purified from bovine milk and
exhibits physico-chemical and immunological similarities with its
avian counterpart; (iii) rat mammary epithelial cells in culture
elaborate this protein and (iv) estrogen and progesterone modulate
its biosynthesis in vivo as well as in vitro.7 In view of reports in the
literature that expression of genes corresponding to milk proteins
and other estrogen-modulated proteins are up-regulated in exper-
imental animal models as well as in women with breast cancer,8–10
we extended our studies to clinically diagnosed human cancer
patients to assess whether RCP is also up-regulated during malig-
nancy and if so, whether a correlation exists between circulatory
RCP levels and stage-dependent neoplasia.
In 1991, we reported our preliminary data, which indicated that
elevated serum RCP levels could be used as a possible biochemical
tumor marker.11 Meanwhile, a study by Ramesh Babu and
Meenakshi,12 seeking a correlation between estrogen receptor sta-
tus, but not severity of the disease, and RCP levels in breast cancer
patients, was somewhat at variance with our findings. We then
undertook an extended phase of our investigation to validate our
earlier findings and carried out, in addition, immunohistochemical
localization of RCP in breast cancer tissue specimens. When these
data were being organized for publication, a similar study based on
our previous findings11 appeared in the literature essentially con-
firming some of our observations.13 However, these authors did
not attempt to correlate RCP levels with either the stage of neo-
plasia or menstrual status of the women patients. In this commu-
nication, we report on the data obtained from both phases of the
investigation, which suggest stage-dependent up-regulation of se-
rum RCP levels in cancer patients.
MATERIAL AND METHODS
Isolation of RCP
RCP was isolated from chicken egg white as described earlier,14
and the purity of the protein was checked by SDS-PAGE. The
protein migrated as a single band and had an apparent molecular
weight of 37 K.
Generation of antibodies
Polyclonal antibodies against RCP were raised in rabbits as
described.14 The monoclonal antibodies (MAbs) to chicken RCP
used in this investigation have been described earlier and shown to
cross-react with purified mammalian, including human, RCP.15,16
Serum samples
Serum samples were collected for routine laboratory investiga-
tions from 43 breast cancer patients from the Kidwai Memorial
Institute of Oncology, Bangalore, India (Study I, 1986/87) and
from 47 breast cancer patients from the Bangalore Institute of
Oncology, Bangalore, India (Study II, 1995/96). Blood samples
were collected from patients at the time of diagnosis or prior to
treatment, and sera were separated and stored at 220°C until
analysis. Control serum samples were obtained through informed
consent from pre-menopausal normal healthy volunteers who had
regular menstrual cyclicity (28 6 4 days); those from post-meno-
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pausal women were obtained through the Health Centre of the
Indian Institute of Science, Bangalore.
Radioimmunoassay of serum
RCP was radiolabeled with 125I for use as a tracer by the
iodogen method.17 RCP was quantified in the serum samples by
liquid-phase radioimmunoassay (LPRIA) using the double anti-
body-polyethylene glycol (PEG) precipitation method standard-
ized for assay of human serum samples.15 Using suitably diluted
serum samples from patients, the levels of RCP in the various
specimens were measured by LPRIA. Intra- and inter-assay vari-
ations were insignificant, and the assay method had a sensitivity
range of 10–0.01 ng. Variations in the standards and the samples
were in the accepted range of 65%. Every sample was assayed in
duplicate in at least three different RIAs, and for every assay, two
calibrator concentrations of 1 ng and 100 pg of RCP were used to
normalize the RIA. The study was carried out double blind, and the
data on the menarche status of individual patients and the stage of
the disease were ascertained from the clinical records retrospec-
tively only after assaying the concentrations of serum RCP. Data
analysis was carried out using Student’s t-test.
In view of the significant (;26%) sequence homology between
RCP and human folate binding protein (FBP), the rabbit polyclonal
antiserum employed in the RIA was tested for cross-reactivity with
FBP and found to be nil even at low FBP dilutions.16
Clinical diagnosis
Clinical staging of the disease was carried out by the Union
Internationale contre le Cancer tumor size, node involvement,
metastasis (UICC-TNM) staging system.
Immunohistochemical localization of RCP in breast cancer
biopsy speciments
Localization of RCP in breast carcinoma cells was accom-
plished by immunohistochemistry18 employing a mixture of spe-
cific murine monoclonal antibodies to chicken RCP. None of these
antibodies cross-reacted with the FBP.16 Tissue specimens ob-
tained from breast cancer patients during surgery were immedi-
ately fixed in Bouin’s fluid and further processed for embedding in
paraffin. Tissue sections (7 mm) were re-hydrated using standard
protocols and incubated with specific antibodies. To test for the
presence of RCP, a mixture of four specific MAbs raised against
RCP was used.15,19 An anti-mucin-1 MAb (115D8, a kind gift of
Dr. J.H.M. Hilgers, Vrije University Hospital, Amsterdam, Neth-
erlands) was used as a positive control to detect malignant cells.20
Normal mouse serum (NMS) IgG was used as a negative control.
After overnight incubation with the primary antibody, the endog-
enous peroxidase activity was blocked using 0.6% H2O2 in meth-
anol, following which the tissue sections were incubated with
rabbit anti-mouse IgG conjugated to horseradish peroxidase (HRP;
Sigma, St. Louis, MO). Binding of the antibodies was visualized
on addition of the substrate diaminobenzidine (1mg/ml in PBS
containing 0.06% H2O2). The sections were counter-stained with
hematoxylin, dehydrated, clarified in xylene and mounted in DPX.
The sections were observed using a Zeiss microscope with a
camera attachment and photographed using Kodak film.
Immunoassay for estrogen and progesterone receptors
Estrogen and progesterone receptors in tissue sections were
localized immunohistochemically using the corresponding specific
antibodies obtained as part of the kits purchased from Novocastra
(New Castle, Tyne, UK). The kits used were NCL-ER-6F1 for
estrogen receptors (ER) and NCL-PG-1 for progesterone receptors
(PR). The secondary antibodies for the assays were purchased
from Lab Vision (Fremont, CA; cat. no. TP-D15-HD). The assays
were carried out per the manufacturer’s instructions.
RESULTS
The RCP levels were assayed in the serum of breast cancer
patients and control subjects using a sensitive radioimmunoas-
say,21 further sensitized and validated for quantification of RCP in
human serum.22 In the case of cycling women, we chose to
measure circulatory levels of RCP at days 18–20 of the menstrual
cycle when they were highest as assessed earlier in the laboratory.
Analysis of the data from both studies showed that the mean level
of RCP in the serum of normal healthy cycling women (n 5 14)
was 3.8 ng/ml (60.72, range 2–6 ng). On the other hand, the mean
level of circulatory RCP in healthy post-menopausal women (n 5
9) was 1.7 ng/ml (60.66, range 1–4 ng). This was anticipated,
since RCP is an estrogen-inducible protein and the estrogen stim-
ulus falls precipitously with the onset of menopause. In contrast, in
patients with clinically confirmed breast carcinoma, the corre-
sponding values for RCP were markedly higher, with median
values of 14.7 ng/ml (65.25, range 3–50 ng) if they were still
cycling (n 5 41) and 17.0 ng/ml (64.6, range 3–50 ng) if they
were post-menopausal (n 5 49). The mean RCP levels in cycling
women were 3- to 4-fold higher (p , 0.01) in patients with breast
carcinoma than in normal control subjects of the same age group.
The difference in the RCP levels was even more significant in
post-menopausal cancer patients, in whom the serum RCP con-
centrations were 9–11 times higher (p , 0.005) than those in their
normal counterparts. However, an overlap in serum RCP levels
from cycling cancer patients with that of normal subjects was seen,
since the values in the normal subjects represented the maximum
RCP level reached during the menstrual cycle.
Table I compares the circulatory RCP concentrations in healthy
women (both pre- and post-menopausal) with those in patients
with clinically confirmed early breast disease as well as those with
advanced breast cancer with metastasis. These results were signif-
icant. The mean level of RCP in women with early breast disease
was 8.4 ng/ml (6.4 and 10.4 ng/ml for Studies I and II, respec-
TABLE I – ANALYSIS OF SERUM RIBOFLAVIN CARRIER PROTEIN (RCP) LEVELS IN BREAST CANCER PATIENTS
(BOTH EARLY AND ADVANCED METASTATIC CANCER)
Serum RCP levels (ng/ml)
Mean 6 SEM Range p-Value
Study I (1986/87)
Normal women
Cycling and postmenopausal (n 5 14) 3.0 6 0.48 1–6
Breast cancer patients
Early (n 5 13) 6.4 6 1.2 2–8 ,0.0051
Advanced, with metastasis (n 5 30) 21.8 6 2.77 8–50 ,0.00052
Study II
Normal women
Cycling and postmenopausal (n 5 9) 2.6 6 1.02 1–5
Breast cancer patients
Early (n 5 21) 10.4 6 5.24 3–22 ,0.0051
Advanced, with metastasis (n 5 26) 19.1 6 4.87 10–31 ,0.0052
1In comparison with normal women.–2In comparison with patients with early breast disease.
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tively) as against 2.8 ng/ml (3.0 and 2.6 ng/ml for Studies I and II,
respectively) in normal women. Here again the elevations in RCP
levels are approximately 3- to 4-fold (p , 0.005). However, the
most striking difference was evident when the RCP levels between
normal subjects (2.8 ng/ml) and those with advanced breast cancer
with metastasis were compared. The mean concentration of serum
RCP in these patients was 20.4 ng/ml (21.8 and 19.1 ng/ml for
Studies I and II, respectively), which was ;7 times higher (p ,
0.0005) than the corresponding serum RCP values encountered in
age-matched control subjects. These observations clearly reveal
that patients with early breast carcinoma harbor higher levels of
serum RCP compared with normal disease-free women and that
these levels are further elevated in patients suffering from ad-
vanced breast cancer with metastasis.
Clinical evaluation of the study subjects was carried out using
the UICC-TNM staging system. It was found that levels of serum
RCP exhibited a significant correlation with the stage of the
disease and the levels were found to be higher in patients with
advanced disease.
At this stage it was important to ascertain whether the malignant
breast tissue accounts for stage-dependent elevated serum RCP
levels in these carcinoma patients. Using the technique of immu-
nohistochemistry, RCP could be localized in cancer tissue using a
pool of anti-RCP-specific MAbs. To confirm neoplastic nature of
the cells in the tissue samples, a MAb (115D8, which specifically
reacts with polymorphic epithelial mucin-1 [MUC1]) was used as
a positive control23 to identify the cancer cells. NMS IgG was used
as a negative control. Tissue samples from six breast cancer
patients were analyzed and the immunohistochemical staining
pattern obtained with the MAb 115D8, anti-RCP MAbs and NMS
IgG for tissues from three of the specimens is shown in Figure 1.
All the breast cancer tissue specimens exhibited intense staining
with the anti-MUC1 MAb 115D8, as expected. The breast cancer
tissues also showed positive staining for the presence of RCP
although the staining pattern varied. Whereas the MUC1 specific
antibody staining was mostly membrane bound, the staining pat-
tern with the anti-RCP MAbs exhibited different distribution pat-
terns depending on whether the cancer was a lobular or infiltrating
ductal carcinoma, or whether the cancerous tissue had an acute
lymphoid response. In lobular carcinomas (specimen 174/95) the
localization of RCP was intra-cytoplasmic as well as peri-nuclear,
whereas in the case of infiltrating ductal carcinoma (specimen
57/95) RCP staining was predominantly intra-cytoplasmic. Sample
101/95 was an infiltrating ductal carcinoma with an acute lym-
phoid response. In this sample most of the cells were inflammatory
cells and hence did not stain for RCP. However, the cancer cells,
which were very few in number, did exhibit both intra-cytoplasmic
and peri-nuclear staining (very faint in Fig. 1). The staining pattern
was specific to RCP as none of the samples showed positive
staining with NMS IgG. Pathological details on the samples and
type of staining pattern observed are collated in Table II.
Analysis of the samples for ER and PR was carried out by
immunohistochemistry. Only one sample (174/95) stained positive
for ER (40%). However, none of the specimens showed staining
for PR. The results are included in Table II.
DISCUSSION
Clinical and experimental evidence has established the central
role of estrogen in the genesis of breast cancer. About 85% of all
breast cancers are estrogen dependent, and these require the hor-
mone for continued growth and differentiation.24 Many studies
have also shown that ER levels are also significantly higher in
malignant breast epithelium compared with normal mammary tis-
sue.25 Since RCP levels are also regulated by estrogen under
physiological conditions, we sought to investigate whether there
was a marked change in RCP levels in patients with breast cancer
compared with their normal age-related counterparts. Hence the
primary aim of our investigations was to compare the serum RCP
levels of individuals who had clinically confirmed breast cancer
with those of normal healthy individuals. Additionally, it was of
interest to investigate whether circulating RCP levels exhibit any
correlation with the disease stage, node involvement and metasta-
sis. We anticipated that if elevated RCP levels reflect the severity
FIGURE 1 – Immunohistochemical staining pattern of specimens from three breast cancer patients. I, sample no. 174/95 (lobular carcinoma);
II, sample no. 57/95 (infiltrating ductal carcinoma); and III, sample no. 101/95 (infiltrating ductal carcinoma with an acute lymphoid response)
seen with anti-mucin MAb 115D8 (a), anti-RCP MAbs (b) and NMS IgG (c). Magnification 3200.
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of the malignant disease, the measurement of this specific protein
could serve as a non-invasive marker for the presence of breast
cancer, to monitor the response to therapy and to assist prognosis.
Furthermore, to ascertain whether the enhanced RCP in the circu-
lation originates directly from malignant cells due to destruction of
original tissue architecture, we used immunohistochemical tech-
niques and specific MAbs to examine the pattern of distribution of
RCP in biopsy tissue specimens from breast cancer patients.
In the present study, the serum RCP concentrations measured in
breast cancer patients were significantly higher than those encoun-
tered in control individuals of the same age group and were
dependent on the stage of the disease. In normal women, RCP
levels in circulation vary in concert with estrogen levels depending
on the stage of the menstrual cycle. It has been reported that RCP
levels in serum were highest 3–4 days after the ovulatory surge of
estrogen.22 These values represent the highest levels of RCP
reached in the circulation, and we chose to use them for compar-
ison with those from cancer patients. In a recent publication by
Rao et al.,13 an average value of 0.7 ng/ml RCP in the circulation
of normal women was reported. The authors were apparently
unaware of hormonal status influencing circulatory RCP levels
during the menstrual cycle and hence the values reported may be
lower than expected. In the present study, as anticipated, we
encountered relatively low levels of RCP in post-menopausal
women. In view of this situation, it is not surprising that the
difference in RCP levels between patients and normal individuals
is much more striking in post-menopausal women. Thus, whereas
the patients with early breast disease exhibit significantly higher
levels of RCP (3- to 4-fold) compared with healthy controls, this
difference is strikingly magnified (.7-fold) in patients with ad-
vanced breast cancer with metastasis.
In attempts to ascertain the likely tissue source of the elevated
RCP in breast cancer, it was indeed very encouraging to find
intense immunostaining of RCP in breast cancer tissues when
specific anti-RCP MAbs were employed for detection. All six
breast cancer tissue samples studied showed positive staining for
RCP as well as for the cancer marker MUC1. However, there
appear to be significant differences in the pattern of immunostain-
ing of RCP compared with MUCI in that RCP is mostly localized
to the cytoplasm and is occasionally peri-nuclear (probably repre-
senting the nascent glycoprotein undergoing modification in the
Golgi complex), whereas MUCI is mostly confined to membranes
of cancer cells.26,27 In normal breast tissue, MUC1 is expressed at
the apical surface of glandular epithelium. However, polarization
is lost in carcinomas, where it is expressed on the entire cell
surface.28 Moreover, MUC1 is overexpressed and deficiently gly-
cosylated in adenocarcinomas and gains access to the circulation in
patients.23 Levels of MUC1 in blood reflect recurrence and pro-
gression of the disease.23,29 Based on these data, it is attractive to
speculate that up-regulated RCP production by invading cancer,
cells coupled with carcinoma-induced destruction of original tissue
architecture, leads to RCP gaining entry into the stroma, lymph
and blood vessels and hence reflects the stage-dependent severity
of malignant condition.
Breast carcinoma is the most common form of cancer in middle-
aged women and is a leading cause of death.30 It is the second most
common form of cancer in women in the Indian subcontinent
according to the population-based registry data (NCRP 94). As
with all neoplastic diseases, early detection is of vital importance
in the eventual prognosis of the disease. The availability of many
reliable screening methods significantly improves the chances of
detection, which in turn helps in the immediate commencement of
therapy. Many prognostic factors, both biological and non-biolog-
ical, are used in clinical practice to identify high-risk individuals
and to plan aggressive multi-modality treatment protocols to
achieve better long-term results. However, since no single absolute
marker has been found so far it, would be advisable to use a panel
of markers. The ER has also been found to be a very useful tool for
prognosis.31,32 Many studies have shown that malignant breast
tissues express a higher level of ER than normal breast tissue,25
and such patients receive objective benefit from hormonal therapy.
However, approximately 30% of ER1 tumors fail to respond to
endocrine therapy, which could be due to tumor heterogeneity or
non-functionality of the hormone receptors.33
In this study we have evaluated the possibility of using RCP as
a marker for breast cancer. Since the protein is estrogen inducible
and since it is well established that up to 85% of breast cancers are
estrogen dependent, it was considered as a possible candidate.
There are several advantages in using RCP as a possible marker for
breast cancer. Its levels can be easily monitored in serum by a
standard sensitive LPRIA, which is very easy to carry out routinely
with a large number of serum samples; this assay is also non-
invasive and hence could be used to study disease progression over
a period of time. RCP is regulated by estrogen under physiological
conditions;1 therefore it was surprising to find that five of the six
breast cancer tissue samples investigated were negative for estro-
gen receptors by the immunochemical assay kit used. However,
some degree of correlation between RCP levels and estrogen
receptor status has been reported by Ramesh Babu and Meenak-
shi12 in a small sample size. There is a possibility, however, that
during carcinogenesis, the regulation of RCP synthesis could be-
come estrogen independent. A similar situation was encountered
TABLE II – PATHOLOGY, STAINING PATTERNS AND RECEPTOR STATUS OF THE SAMPLES
Sample
no.
Type of cancer
Staining pattern
ER status PR status
With Mab 115D8 With RCP Mabs
174/95 Lobular carcinoma of
the breast (cribiform
pattern seen)
Membrane-bound and
intracytoplasmic
staining
Intracytoplasmic staining and
perinuclear staining
Positive
(40%)
Negative
157/95 Infiltrating ductal
carcinoma
Membrane-bound staining Intracytoplasmic staining; no perinuclear
staining
Negative Negative
121/95 Infiltrating ductal
carcinoma
Membrane-bound staining Intracytoplasmic staining; no perinuclear
staining
Negative Negative
105/95 Lobular carcinoma of
the breast
Uniform membrane-
bound and
intracytoplasmic
staining
Intracytoplasmic and perinuclear
staining in 50% of cancer cells
Negative Negative
101/95 Infiltrating ductal
carcinoma of the
breast showing an
acute lymphoid
response
Tumour cells show
membrane-bound and
intracytoplasmic
staining, Lymphocytes
are negative
Intracytoplasmic and perinuclear
staining in cancer cells; most of the
cells are inflammatory cells, which do
not show staining
Negative Negative
57/95 Infiltrating ductal
carcinoma with
abundant
desmoplasia (fibrous
tissue proliferation)
Very intense membrane-
bound staining
Very dense intracytoplasmic staining Negative Negative
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with cathepsin D, another independent breast cancer marker in
which the synthesis of the protein is de-linked from regulation by
estrogen under certain conditions of malignancy. It has been
shown that in both the estrogen receptor-positive and -negative
breast cancer cell lines the mRNA coding for pro-cathepsin D is
over-expressed.34 This is further supported by the observation that
markedly enhanced levels of serum RCP were found in post-
menopausal women with breast carcinoma, whereas their healthy
counterparts exhibited very low levels of the protein. The elevated
levels of RCP in circulation in breast cancer patients appear to
originate from the cancer tissue since patients with metastasis
showed markedly higher levels of RCP than patients with localized
tumor, the tumor cell burden being higher during metastasis. We
have earlier observed that immunochemical distribution of RCP in
normal breast tissue is almost exclusively localized to ductal
epithelium, whereas, in the present study with the cancer tissues,
this pattern seems to have altered significantly with respect to RCP
staining associated with malignancy. It is conceivable therefore
that immunohistochemical localization of RCP using fine needle
biopsy specimens maybe useful in early diagnosis of in situ car-
cinomas. The ability to immunolocalize RCP in paraffin-embedded
tissue sections should make it possible to obtain data on RCP in
retrospective series of patients with breast cancer in relation to
clinical diagnosis/prognosis. Further research efforts on these lines
should be useful in exploring RCP as a biochemical marker for
malignancies of breast. The above preliminary data were obtained
retrospectively with a limited population of cancer patients, and
they await confirmation in a larger number of patients. It may be
useful to assess levels of RCP in the same patient over a long
period of time starting from the stage of initial diagnosis through
any treatment regimes since it is likely that assay of serum RCP
may become useful as a marker to assess prognosis and follow-up
therapy and to classify risk factors in breast cancer patients.
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